Not all individuals with PKU respond to sapropterin therapy. Genetic testing and a trial period are often used to determine whether a neonate will benefit from the medication. Approximately 20-56% of individuals with PKU have a form of the disorder that is responsive to sapropterin. Those who do respond can see significant reductions in blood phenylalanine levels, allowing for a more flexible diet and improved quality of life.
